美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

291.47

-4.9900-1.68%

盘后：291.470.00000.00%16:39 EDT

成交量：17.12万

成交额：4,989.66万

市值：345.83亿

市盈率：-78.71

高：293.17

开：289.73

低：287.00

收：296.46

数据加载中...

总览公司新闻公告

百济神州7月7日成交额为7745.23万美元

中国医药行业：理性看待创新药估值寻找优秀公司的买点

创新药大牛市继续，最受益也是中国最强的创新药龙头，高瓴资本重仓公司！

2025年医药市场格局重塑：创新药企突围与投资新机遇分析及数据解读

剔除CXO，创新药指数迎“提纯”！

市值超越恒瑞医药，百济神州凭什么？

创新药产业迎“黄金时代”：指数“提纯”助力投资精准化

环球老虎财经app

【券商聚焦】招银国际维持百济神州(06160)美股买入评级指CDK4抑制剂显示初步疗效

正大天晴 HER2 双抗首次启动 III 期临床

Insight数据库

百济神州(06160)根据2016期权及激励计划授出合共4.38万股受限制股份单位

官宣了！单国洪加入百济神州

管线大爆发！百济神州血液瘤“三驾马车”成型，实体瘤8大POC蓄势，构建全球化新范式

百济神州7月2日成交额为8588.44万美元

中国药品研发实力排行榜如何解码医药行业价值投资密码？

中证500医药卫生指数下跌1.0%，前十大权重包含百济神州等

百济神州7月1日成交额为8478.41万美元

【深度拆解】创新药：医保红利+出海狂飙，谁将主宰万亿赛道？

新事丨五家CXO公司，被剔除出创新药指数

单国洪即将加入百济神州向吴晓滨汇报

南方财经网

百济神州6月30日成交额为9745.38万美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ONC/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":291.47,"timestamp":1753473600000,"preClose":296.46,"halted":0,"volume":171194,"hourTrading":{"tag":"盘后","latestPrice":291.47,"preClose":291.47,"latestTime":"16:39 EDT","volume":1979,"amount":576814.86,"timestamp":1753475983218},"delay":0,"floatShares":75541600,"shares":118650120,"eps":-3.70325,"marketStatus":"休市中","change":-4.99,"latestTime":"07-25 16:00:00 EDT","open":289.73,"high":293.165,"low":287,"amount":49896623.98421,"amplitude":0.020795,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":296.46,"preHourTrading":{"tag":"盘前","latestPrice":291,"preClose":296.46,"latestTime":"09:28 EDT","volume":38,"amount":11165.538480000001,"timestamp":1753450080032},"postHourTrading":{"tag":"盘后","latestPrice":291.47,"preClose":291.47,"latestTime":"16:39 EDT","volume":1979,"amount":576814.86,"timestamp":1753475983218},"volumeRatio":0.40463067027862526,"impliedVol":0.4268,"impliedVolPercentile":0.4714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.40463067027862526,"shares":118650120,"dividePrice":0,"high":293.165,"amplitude":0.020795,"preClose":296.46,"low":287,"week52Low":155.75,"pbRate":"9.88","psRate":"8.28","week52High":300,"institutionHeld":0,"latestPrice":291.47,"eps":-3.70325,"divideRate":0,"volume":171194,"delay":0,"ttmEps":-3.70325,"open":289.73,"prevYearClose":184.71,"prevWeekClose":294.55,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":294.55,"twentyDayClose":254.49,"sixtyDayClose":249.77,"earningDate":1754409600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2549599755","title":"百济神州7月7日成交额为7745.23万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549599755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549599755?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 12:29","pubTimestamp":1751948965,"startTime":"0","endTime":"0","summary":"美东时间2025年7月7日，百济神州成交额为7745.23万美元，成交额较昨日增加82.68%，当日成交量为32.09万股。百济神州于2025年7月7日跌1.83%，报240.99美元，该股过去5个交易日跌0.09%，年初至今涨30.47%，过去60日涨15.08%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708122927a43d2e69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708122927a43d2e69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2549596030","title":"中国医药行业：理性看待创新药估值 寻找优秀公司的买点","url":"https://stock-news.laohu8.com/highlight/detail?id=2549596030","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549596030?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 00:00","pubTimestamp":1751904000,"startTime":"0","endTime":"0","summary":"中国创新药的研发实力具备全球竞争力，创新药出海趋势将长期持续。创新药商保目录即将落地，对行业短期影响有限，长期将打开创新药支付空间。7 月1 日，医保局发布了医保目录和商保创新药目录调整工作方案，预计将于10-11 月公布结果。商保创新药目录采用价格协商的形式，由商保专家、医保部门与药企进行价格协商。但商业健康保险赔付率较低，2023 年商业健康保险赔付额仅为3,848 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708120124a69c4119&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708120124a69c4119&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","01530","BK1219","ONC","06699","02273","02367","01801","BK1161"],"gpt_icon":0},{"id":"2549831645","title":"创新药大牛市继续，最受益也是中国最强的创新药龙头，高瓴资本重仓公司！","url":"https://stock-news.laohu8.com/highlight/detail?id=2549831645","media":"萝卜投研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549831645?lang=zh_cn&edition=fundamental","pubTime":"2025-07-07 15:14","pubTimestamp":1751872499,"startTime":"0","endTime":"0","summary":"高瓴资本是百济神州的十大股东之一！经调整后，公司实现营业利润11.71亿元，净利润8.85亿元。公司总资产为421亿元，归属于上市公司股东的所有者权益为252亿元。继首季度盈利之后，6 月 26 日，百济神州举行了投资者研发日活动。HER2双抗泽尼达妥单抗于上个月在中国获批上市，直指HER2阳性实体瘤群体尚未满足的临床需求。其二为2025年创新药头部上市公司扭亏，2026年更多公司盈利。短期来看，2025年有望成为创新药企业收入集体放量的起点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707151714a43b367b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707151714a43b367b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2298322129.HKD","LU1861214812.USD","BK4605","LU1861220033.SGD","BK4526","LU2360107325.USD","BK4512","06160","IE00BZ199S13.USD","LU0124384867.USD","BK4588","LU1861215975.USD","BK4141","BK4585","LU0724618433.USD","BK4139","LU2357305700.SGD","LU1854103824.USD","LU1720051108.HKD","LU1978683503.SGD","ONC","IE00BD6J9T35.USD","LU1861219969.SGD","LU1854104046.USD","LU1720051017.SGD","ON","LU1548497426.USD","LU0348723411.USD"],"gpt_icon":0},{"id":"2549010653","title":"2025年医药市场格局重塑：创新药企突围与投资新机遇分析及数据解读","url":"https://stock-news.laohu8.com/highlight/detail?id=2549010653","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549010653?lang=zh_cn&edition=fundamental","pubTime":"2025-07-07 11:01","pubTimestamp":1751857263,"startTime":"0","endTime":"0","summary":"行业数据显示，全球BCL-2抑制剂市场将在2028年达到52亿美元规模，而乳腺癌靶向药物市场规模更将突破163亿美元，为创新药企提供结构性增长空间。2025年医药市场呈现出鲜明的结构性特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707124736979c9a9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707124736979c9a9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","LU1997245094.SGD","LU2488822045.USD","LU2495084118.USD","ONC","162414","BK0012","BK0028","BK0188","LU0405327148.USD","BK0183","688235","01276","600276","LU0405327494.USD","LU1064131003.USD","LU1064130708.USD","159938","BK0060","LU2148510915.USD","BK0239","LU1997244956.HKD","LU2328871848.SGD","LU1969619763.USD","06160","LU1655091616.SGD","LU1328615791.USD","LU1997245177.USD","BK0196"],"gpt_icon":0},{"id":"2549718305","title":"剔除CXO，创新药指数迎“提纯”！","url":"https://stock-news.laohu8.com/highlight/detail?id=2549718305","media":"侃见财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549718305?lang=zh_cn&edition=fundamental","pubTime":"2025-07-07 10:44","pubTimestamp":1751856299,"startTime":"0","endTime":"0","summary":"在板块高歌猛进之际，6月30日，恒生指数公司宣布对恒生港股通创新药指数进行关键修订：明确剔除CXO企业，打造“纯度”100%的创新药指数。这次指数修订，将一次性剔除5家CXO企业、合计权重约20%，它们年初以来的涨幅均落后于指数整体表现。修订规则生效后，恒生港股通创新药指数将成为目前ETF跟踪的指数中首批“纯度”达100%的创新药指数。回测显示，指数经过“提纯”后表现将有全面的提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707104842a699ffa3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707104842a699ffa3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","06160","CXO","BK4526","688235","600276","01801","ONC"],"gpt_icon":0},{"id":"2549306385","title":"市值超越恒瑞医药，百济神州凭什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2549306385","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549306385?lang=zh_cn&edition=fundamental","pubTime":"2025-07-07 10:34","pubTimestamp":1751855640,"startTime":"0","endTime":"0","summary":"　　百济神州市值超越恒瑞医药背后，是中国创新药从“仿制跟随”到“全球引领”的一次历史性跨越。其中，国内创新药龙头药企百济神州首次上榜，排名第44位，一举超越了国内“医药一哥”恒瑞医药（46名），成为外界热议的话题。　　财报数据显示，2024年全年，百济神州实现总营收达272.14亿元，同比大增56.19%。2024年，恒瑞医药实现净利润63.37亿元，同比大增47.28%，创出历史新高。受此消息提振，百济神州股价持续上涨。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-07-07/doc-inferezn9899533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1997244956.HKD","LU1969619763.USD","06160","600276","LU0405327148.USD","BK0028","LU1064131003.USD","LU0405327494.USD","BK1161","BK0239","LU1655091616.SGD","01276","LU0588546209.SGD","BK0196","LU0307460666.USD","BK0188","BK1500","BK1191","BK4526","LU1997245177.USD","BK0060","LU2495084118.USD","LU1328615791.USD","LU2148510915.USD","BK0012","LU1064130708.USD","BK0183","BK1588","LU2488822045.USD","BK1583","LU1997245094.SGD","ONC","688235","BK4139","LU2328871848.SGD"],"gpt_icon":0},{"id":"2548049393","title":"创新药产业迎“黄金时代”：指数“提纯”助力投资精准化","url":"https://stock-news.laohu8.com/highlight/detail?id=2548049393","media":"环球老虎财经app","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548049393?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 19:00","pubTimestamp":1751626802,"startTime":"0","endTime":"0","summary":"创新药指数修订“提纯”6月30日，恒生港股通创新药指数宣布修订编制方案，明确剔除CXO企业。也就是说，此次调整后，该指数成分股将全部由创新药研发企业构成，等修订生效后，该指数将成为ETF跟踪指数中首批“纯度”达100%的创新药指数。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704193508a436e2cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704193508a436e2cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","ONC","LU0405327148.USD","BK0239","LU1997245094.SGD","688235","01093","01530","LU1997244956.HKD","BK0028","BK0012","SBHMY","LU1997245177.USD","LU1655091616.SGD","02196","LU1064131003.USD","BK0196","BK0188","ZLAB","01177","01276","09688","01801","600196","159992","LU0405327494.USD","06160","LU1064130708.USD","LU1969619763.USD","03933","LU2495084118.USD","09926","BK0183","LU2488822045.USD","600276","LU2148510915.USD","BK0060","LU1328615791.USD","06990","LU2328871848.SGD"],"gpt_icon":0},{"id":"2548513853","title":"【券商聚焦】招银国际维持百济神州(06160)美股买入评级 指CDK4抑制剂显示初步疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2548513853","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548513853?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 13:44","pubTimestamp":1751607842,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，百济神州 CDK4抑制剂显示出良好的血液安全性，并降低了中性粒细胞减少发生率。百济的CDK4抑制剂BGB-43395展示出良好的血液学安全性，这得益于其更优的CDK4/CDK6选择性，从而减少了CDK6介导及非靶向的毒性。CDK4抑制剂的疗效数据仍在成熟中。泽布替尼在CLL一线及复发/难治患者中持续领跑新处方数，并已成为美国销售额最高的BTK抑制剂。公司计划于2026年为BGB-16673在CLL中提交加速批准申请。维持美股买入评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1961652","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","06160","ONC"],"gpt_icon":0},{"id":"2548693336","title":"正大天晴 HER2 双抗首次启动 III 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2548693336","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548693336?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 08:04","pubTimestamp":1751587443,"startTime":"0","endTime":"0","summary":"近日，正大天晴在ClinicalTrials.gov 官网上登记了一项TQB2930 用于HER2 阳性乳腺癌的 III 期临床试验。公开资料显示，这是该药启动的首个III 期。2025 年 ASCO 大会上公布的是该试验中队列 4 的数据，旨在评估 TQB2930 联合化疗对至少接受过两线治疗的 HER2 阳性乳腺癌患者的安全性和有效性。截至 2024 年 12 月 15 日，已有 55 例患者接受了 TQB2930 联合化疗治疗。除此之外，正大天晴TQB2930 和康宁杰瑞/石药集团Anbenitamab-KN-026 已进入 III 期临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704080948a4ce2d9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704080948a4ce2d9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK0239","ONC","688235"],"gpt_icon":0},{"id":"2548743878","title":"百济神州(06160)根据2016期权及激励计划授出合共4.38万股受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2548743878","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548743878?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 16:56","pubTimestamp":1751532966,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年6月30日，董事会薪酬委员会根据2016期权及激励计划的条款授予216名承授人合共4.38万股美国存托股份受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","BK4526","LU0588546209.SGD","ONC","BK1583","BK4139","BK1161","LU1969619763.USD","BK1588","688235","BK0239","LU0307460666.USD","LU2328871848.SGD","BK1500"],"gpt_icon":0},{"id":"2548878854","title":"官宣了！单国洪加入百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2548878854","media":"谈思生物","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548878854?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 15:00","pubTimestamp":1751526058,"startTime":"0","endTime":"0","summary":"武田中国前总裁单国洪8月加盟百济神州，执掌大中华区及中亚南亚业务，加速跨国药企新兴市场布局。多家自媒体消息显示，原武田制药全球高级副总裁、中国区总裁单国洪将于2025年8月18日正式加入百济神州，担任大中华区及中亚、南亚区域总经理，届时将向吴晓滨博士汇报工作。6月17日上午，武田全球生物制药及国际市场业务集团总裁施睿娜向内部员工宣布了单国洪的人事变动：其决定离开武田，寻求外部发展机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703150859a72c1985&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703150859a72c1985&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK4139","688235","BK4526"],"gpt_icon":0},{"id":"2548829202","title":"管线大爆发！百济神州血液瘤“三驾马车”成型，实体瘤8大POC蓄势，构建全球化新范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2548829202","media":"药时代","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548829202?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 12:44","pubTimestamp":1751517855,"startTime":"0","endTime":"0","summary":"泽布替尼只是开始，百济神州血液瘤的上市产品格局即将焕新，新王牌索托克拉已在华申报上市，并预计在今年下半年推进全球申报。基于这些积极结果，百济神州已开启3项头对头全球III期临床。百济神州在实体瘤的故事由替雷利珠单抗领衔讲述。基于此，百济神州将在今年Q3开放乳腺癌和妇科恶性肿瘤的肿瘤特异性扩展队列，以进一步确认BG-C9074在B7-H4高表达肿瘤患者中的疗效和安全性。在肺癌领域，百济神州正在打造行业领先的产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703125051a4cc84b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703125051a4cc84b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK4526","06160","ONC","BK4139"],"gpt_icon":0},{"id":"2548829200","title":"百济神州7月2日成交额为8588.44万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548829200","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548829200?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 12:39","pubTimestamp":1751517578,"startTime":"0","endTime":"0","summary":"美东时间2025年7月2日，百济神州成交额为8588.44万美元，成交额较昨日增加1.30%，当日成交量为35.32万股。百济神州于2025年7月2日跌0.34%，报244.32美元，该股过去5个交易日跌8.54%，年初至今涨32.27%，过去60日涨2.44%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703123944a4cc81c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703123944a4cc81c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2548847204","title":"中国药品研发实力排行榜如何解码医药行业价值投资密码？","url":"https://stock-news.laohu8.com/highlight/detail?id=2548847204","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548847204?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 09:44","pubTimestamp":1751507096,"startTime":"0","endTime":"0","summary":"2016年9月24日，《中国药品研发实力排行榜》首次发布，并在之后每年持续更新，期间始终以药企“创新属性”为核心，通过“量化研发实力”的方式精准、直接的反映出“药企成长潜力”，是医药行业投资极具价值的参照物。2025年6月20日，最新一版《中国药品研发实力排行榜》已成功发布，新一年投资机会已经更新，还不赶紧看看。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703094829a4cc3244&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703094829a4cc3244&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK0239","01801","03692","688235","06160","600276"],"gpt_icon":0},{"id":"2548981654","title":"中证500医药卫生指数下跌1.0%，前十大权重包含百济神州等","url":"https://stock-news.laohu8.com/highlight/detail?id=2548981654","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548981654?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 23:16","pubTimestamp":1751469403,"startTime":"0","endTime":"0","summary":"金融界7月2日消息，上证指数高开震荡，中证500医药卫生指数 下跌1.0%，报10145.27点，成交额159.01亿元。数据统计显示，中证500医药卫生指数近一个月上涨1.14%，近三个月上涨1.16%，年至今上涨5.50%。从中证500医药卫生指数持仓样本的行业来看，医药卫生占比100.00%。在样本公司有特殊事件发生，导致其行业归属发生变更时，将对中证500行业指数样本进行相应调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/02231651451531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","159982","BK4139","06160","BK1161","399905","BK0239","BK1588","000001.SH","688235","BK4526","000905.SH","ONC","LU2328871848.SGD","LU1969619763.USD","LU0588546209.SGD","BK1500","LU0307460666.USD"],"gpt_icon":0},{"id":"2548953859","title":"百济神州7月1日成交额为8478.41万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548953859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548953859?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 12:29","pubTimestamp":1751430587,"startTime":"0","endTime":"0","summary":"美东时间2025年7月1日，百济神州成交额为8478.41万美元，成交额较昨日减少13.00%，当日成交量为34.74万股。百济神州于2025年7月1日涨1.28%，报245.16美元，该股过去5个交易日跌8.11%，年初至今涨32.73%，过去60日跌7.25%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702122950a729bdd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702122950a729bdd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2548833346","title":"【深度拆解】创新药：医保红利+出海狂飙，谁将主宰万亿赛道？","url":"https://stock-news.laohu8.com/highlight/detail?id=2548833346","media":"财经早餐","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548833346?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 06:34","pubTimestamp":1751409291,"startTime":"0","endTime":"0","summary":"一支抗癌药，从实验室到患者手中，需要10年、20亿美金——但中国药企正将这场“生死竞速”缩短至5年。当医保“超级买单人”砸下4100亿，海外巨头疯抢中国Biotech管线时，我们是否站在了创新药产业的历史性拐点？中国创新药产业已进入“政策驱动型增长”新阶段。核心数据印证：医保基金累计支付谈判药品4100亿元，直接撬动6000亿销售规模。当中国药企在ASCO的演讲台上与默沙东同台竞技时，资本市场需要重新定价“中国创新”的全球价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702063831a4c9adc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702063831a4c9adc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK1161","BK1574","BK1583","LU2328871848.SGD","01801","06160","BK1589","LU2488822045.USD","ONC","688235","06978"],"gpt_icon":0},{"id":"2548000672","title":"新事丨五家CXO公司，被剔除出创新药指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2548000672","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548000672?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 22:28","pubTimestamp":1751380123,"startTime":"0","endTime":"0","summary":"6月30日，恒生港股通创新药指数宣布修订编制方案，明确剔除CXO公司，聚焦创新药核心公司。根据新的编制方案，药明生物、药明康德、金斯瑞、药明合联、晶泰控股5家公司，将从恒生港股通创新药指数中剔除。截至6月30日，恒生港股通创新药精选指数上半年涨幅达到58.95%。修订后，恒生港股通创新药指数前五大成分股，分别是信达生物、百济神州、康方生物、石药集团、中国生物制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701223315a4c9336d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701223315a4c9336d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526","02228","CXO"],"gpt_icon":0},{"id":"2548022919","title":"单国洪即将加入百济神州 向吴晓滨汇报","url":"https://stock-news.laohu8.com/highlight/detail?id=2548022919","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548022919?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 14:13","pubTimestamp":1751350433,"startTime":"0","endTime":"0","summary":"南方财经7月1日电，原武田制药全球高级副总裁、武田中国总裁单国洪(SeanShan)将于2025年8月18日加入百济神州，出任大中华区、中亚和南亚区域总经理，并向吴晓滨汇报。单国洪将主导百济神州在大中华区、中亚和南亚这一关键增长区域的运营与战略发展，同时还将推进构建高效协同的区域运营模式，最大程度响应患者需求，助力公司全球化战略的深入实施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507013445012475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4139","BK1583","06160","BK1588","LU0588546209.SGD","02197","LU2328871848.SGD","ONC","BK4526","BK1500","LU1969619763.USD","LU0307460666.USD"],"gpt_icon":0},{"id":"2548026060","title":"百济神州6月30日成交额为9745.38万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548026060","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548026060?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 12:14","pubTimestamp":1751343249,"startTime":"0","endTime":"0","summary":"美东时间2025年6月30日，百济神州成交额为9745.38万美元，成交额较昨日增加0.53%，当日成交量为40.21万股。百济神州于2025年6月30日涨0.36%，报242.07美元，该股过去5个交易日跌6.0%，年初至今涨31.05%，过去60日跌11.9%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701121416a4c80ca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701121416a4c80ca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":4,"totalSize":166,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盘前","dateTimestamp":1756526400000,"actualEps":null},{"date":"2025-08-06","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.48,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-25","current":-89.648478,"percent":0.003448,"low":-89.808695,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"high":-19.234246,"avg":-41.089589,"sd":19.328162,"marketCap":35175014575},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575}],"updateTime":1753608655352}}}